According to the European Medicines Agency (EMA), these can also be given after just three months. Notwithstanding current recommendations to administer the booster after six months, “currently available data support a safe and effective booster dose as early as three months after completion of basic immunization,” EMA Director of Immunization Strategy Marco Cavaleri said yesterday.
Cavaleri also expressed optimism about an early approval for U.S. manufacturer Novavox’s Corona vaccine, which is one of the protein vaccines. It could happen this year, he said. That would add a fifth authorized Corona vaccine to the arsenal available in the EU.
The Novavax product, unlike the previously authorized vaccines, is neither an mRNA vaccine – like the preparations from Biontech and Moderna – nor a vector vaccine like those from Astrazeneca and Johnson & Johnson. The vaccine contains tiny particles consisting of a laboratory-produced version of the spike protein of Sars-CoV-2.
- source: derstandard.at/picture:pixabay.com
This post has already been read 421 times!
